Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MB-CART 19.1 by Miltenyi Biomedicine for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL)....
MB-CART 19.1 by Miltenyi Biomedicine for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL)....
MB-CART 19.1 by Miltenyi Biomedicine for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to...
MB-CART 19.1 by Miltenyi Biomedicine for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for Follicular Lymphoma: Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for Follicular Lymphoma. According to GlobalData,...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for Mantle Cell Lymphoma: Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for Mantle Cell Lymphoma. According to...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...
MB-dNPM1-TCR.1 by Miltenyi Biomedicine for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
MB-dNPM1-TCR.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According...
MB-CART 19.1 by Miltenyi Biomedicine for Systemic Lupus Erythematosus: Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for Systemic Lupus Erythematosus. According to...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According...